# Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

> **NCT03083990** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** IBI305(Bevacizumab Biosimilar)
- **DRUG:** Avastin(Bevacizumab)

## Key facts

- **NCT ID:** NCT03083990
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2017-08-17
- **Final completion:** 2017-08-17
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083990, "Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03083990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*